1-4 of 4
Richard Marais
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A185: Combining unbiased network analysis and cancer genomics to guide precision medicine-oriented early-phase clinical trials

Pedro Torres-Ayuso, Sudhakar Sahoo, Christopher Chester, Cassandra Hodgkinson, Melanie Galvin, Hui Sun Leong, Kristopher Frese, Richard Marais, Caroline Dive, Matthew Krebs, John Brognard
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A185.
https://doi.org/10.1158/1535-7163.TARG-17-A185
Published: 01 January 2018
View article titled, Abstract A185: Combining unbiased network analysis and cancer genomics to guide precision medicine-oriented early-phase clinical trials
Journal Articles

The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells

Teresa Delgado-Goni, Maria Falck Miniotis, Slawomir Wantuch, Harold G. Parkes, Richard Marais, Paul Workman, Martin O. Leach, Mounia Beloueche-Babari
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (12): 2987–2999.
https://doi.org/10.1158/1535-7163.MCT-16-0068
Published: 01 December 2016
View article titled, The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells
Open the PDF for The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells in another window
Includes: Supplementary data
Journal Articles

Abstract PL02-02: BRAF and RAS signaling in cancer: From biology to therapeutics.

Richard Marais
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): PL02-02.
https://doi.org/10.1158/1535-7163.TARG-11-PL02-02
Published: 12 November 2011
View article titled, Abstract PL02-02: BRAF and RAS signaling in cancer: From biology to therapeutics.
Journal Articles

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Udai Banerji, Annette Affolter, Ian Judson, Richard Marais, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 737–739.
https://doi.org/10.1158/1535-7163.MCT-08-0145
Published: 15 April 2008
View article titled, <em>BRAF</em> and <em>NRAS</em> mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
Open the PDF for <em>BRAF</em> and <em>NRAS</em> mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors in another window